FINWIRES · TerminalLIVE
FINWIRES

ASX:HLS

8 stories mentioning ASX:HLSUpdated just now

Every FINWIRES story that references ASX:HLS, newest first.

What's the latest news on ASX:HLS?

Asia

Market Chatter: Healius Agrees to Sell Agilex Biolabs to Novotech for About $150 Million, Says AFR

Healius (ASX:HLS) has agreed to sell Agilex Biolabs to Novotech in a AU$150 million deal, according to a Thursday report by the Australian Financial Review, citing people with knowledge of the deal.The report said Healius finalised terms with Novotech's owners on Thursday, with a disclosure detailing the deal expected imminently.Novotech is a clinical research organization valued at more than $3 billion and controlled by global buyout firm TPG alongside Singaporean investors GIC and Temasek, per the report.Healius did not immediately respond torequest for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:HLS
Asia

Healius Says Citigroup Becomes Substantial Holder, Shares Up 3%

Healius (ASX:HLS) said Citigroup became a substantial holder of the firm on Sept. 4 after acquiring 5.7% voting power, according to a Tuesday Australian bourse filing.Citigroup Global Markets Australia and related bodies corporate in the Citigroup group of companies hold 41.7 million ordinary shares of the firm, as of Sept. 4.Its shares rose 3% in recent trading on Tuesday.

ASX:HLS
Asia

Update: Healius Signs National Agreement Framework With Ramsay Health Care; Shares Up 6%

(Updates to add stock movement in the headline and the last paragraph)Healius (ASX:HLS) entered into a national agreement framework with subsidiaries of Ramsay Health Care (ASX:RHC), effective Wednesday, according to an Australian bourse filing on June 26 after market hours.The framework replaces existing pathology leases and service arrangements with standardized agreements across 13 Ramsay-operated hospitals in New South Wales, Victoria, Queensland and Western Australia, per the filing.The new contracts, with initial terms of two to five years, are expected to generate around AU$45 million in annual revenue, subject to stable customer demand and economic conditions, the filing added.Healius' shares rose past 6% in recent Monday trade, while Ramsay Health Care gained 2%.

ASX:HLSASX:RHC
Asia

Healius Signs National Agreement Framework With Ramsay Health Care

Healius (ASX:HLS) entered into a national agreement framework with subsidiaries of Ramsay Health Care (ASX:RHC), effective Wednesday, according to an Australian bourse filing on June 26 after market hours.The framework replaces existing pathology leases and service arrangements with standardized agreements across 13 Ramsay-operated hospitals in New South Wales, Victoria, Queensland and Western Australia, per the filing.The new contracts, with initial terms of two to five years, are expected to generate around AU$45 million in annual revenue, subject to stable customer demand and economic conditions, the filing added.

ASX:HLSASX:RHC
Asia

Healius Says Macquarie Group Ceases to Be a Substantial Holder

Healius (ASX:HLS) said Macquarie Group (ASX:MQG) and its controlled bodies corporate ceased to be substantial holders of the firm on Tuesday, according to a Friday Australian bourse filing.Its shares rose 2% in recent trading on Friday

ASX:HLSASX:MQG
Asia

Healius Says Macquarie Becomes Substantial Holder

Healius (ASX:HLS) said Macquarie Group (ASX:MQG) and its controlled bodies corporate acquired 5.06% voting power in the firm on Monday, becoming a substantial holder, according to a Thursday Australian bourse filing.Macquarie holds 36.7 million securities of the firm.Its shares rose over 2% in recent trading on Thursday.

ASX:HLS
Asia

Healius Issues Fiscal Year 2026 Guidance Amid Pathology Pressures; Explores Sale of Agilex Biolabs; Shares Drop 21%

Healius (ASX:HLS) said its pathology volumes grew 1.2% and revenue 3.5% in the fiscal first half, but volumes declined by 0.4% and revenue growth came in at a slower 2.4% for the 10 months to April, according to a Wednesday filing with the Australian bourse.The company now expects fiscal year underlying earnings before interest and tax of between AU$30 million and AU$35 million, per the filing.Healius' pathology labor costs will be impacted by AU$1.8 million in the fiscal fourth quarter due to the Fair Work Commission's initial findings on gender-based undervaluation. These costs increased 0.8% in the 10 months to April, compared with previous guidance of broadly flat levels for the fiscal year, the company said.It added that Australia's federal budget contains no new funding for pathology, a sector that is already under pressure and operating under an indexation freeze for most tests. The company has cut staff and closed collection centers and regional laboratories due to insufficient funding.Additionally, Healius has engaged UBS Securities Australia to help explore a potential sale of Agilex Biolabs, which operates as a standalone business within Healius. The strategic review follows "several unsolicited approaches from credible parties," the company said.Healius shares fell 21% in recent Wednesday trade and earlier hit an all-time low.

ASX:HLS
Asia

Healius Says Macquarie Ceases to Be Substantial Holder

Healius (ASX:HLS) said Macquarie Group and its controlled entities have ceased to be a substantial holder in the company on April 8, according to a Monday Australian bourse filing.The company's shares rose 1% in recent Monday trade.

ASX:HLS

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:HLS in your portfolio
WheelAI
WheelAI
Analyze ASX:HLS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:HLS